Navigation Links
PAREXEL Expands Alliance Network to Support Early Phase Patient Studies, Establishes Collaboration With University Hospitals Bristol NHS Foundation Trust
Date:1/23/2012

regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand.
For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements.  Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "will," "would," "could," "should,"  "targets," and similar expressions are also intended to identify forward-looking statements.  The forward-looking statements in this release involve a number of risks and uncertainties.  The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release.  Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings, including the anticipated additional restructuring charges of approximately $4 million in the second quarter of Fiscal Year 2012; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug,  medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of h
'/>"/>
SOURCE PAREXEL International Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. PAREXEL Announces Date of Second Quarter Fiscal Year 2012 Earnings Release and Conference Call
2. PAREXEL Strengthens Late Phase and Observational Research Capabilities With Expert Team to Help Biopharma Meet Commercialization Goals
3. PAREXEL Advances Early Phase CNS Research Capabilities With Leading Medical Imaging Technology
4. UCB and PAREXEL Sign Strategic Partnership Agreement
5. PAREXEL International to Present at Lazard Capital Markets Healthcare Conference and Citi Small/Mid Cap Conference
6. PAREXEL Commercialization Experts to Present Best-Practice Approaches for Demonstrating Product Value at ISPOR Annual European Congress
7. PAREXEL Reports First Quarter Fiscal Year 2012 Financial Results
8. PAREXEL Expands Commercialization Capabilities With Dedicated Team to Help Biopharma Companies Demonstrate Product Value
9. New PAREXEL Podcast Series to Deliver Clinical Development and Commercialization Thought Leadership
10. PAREXEL and National University of Singapore Establish Program in Singapore to Meet Increasing Demand in Asia for Clinical Research Talent
11. PAREXEL Announces Date of First Quarter Fiscal Year 2012 Earnings Release and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... SAN DIEGO , Feb. 27, 2015 /PRNewswire/ ... three-dimensional biology company focused on delivering breakthrough 3D ... , President and Chief Executive Officer, will present ... "We invite you to join us for ... to provide updates on our commercial launch of ...
(Date:2/27/2015)...  Uroplasty, Inc. (NASDAQ: UPI ), a medical ... products to treat voiding dysfunctions, today announced that it ... Tuesday, March 10, 2015. Rob Kill , President ... Officer, will present at 4:00 p.m. Pacific Time and ... at the Ritz Carlton in Laguna Niguel, ...
(Date:2/27/2015)... and JERUSALEM , Feb. 27, 2015 ... octreotide capsules, its lead product for the orphan condition ... Series E financing round. Participants in the financing included ... an undisclosed blue chip public investment fund, as well ... Health Ventures, Abingworth and ARCH Venture Partners. ...
Breaking Medicine Technology:Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 2Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 3Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 4Uroplasty to Participate in the 27th Annual ROTH Conference 2Chiasma Announces Completion of $70 Million Series E Financing 2Chiasma Announces Completion of $70 Million Series E Financing 3
(Date:3/1/2015)... ERISAPros is pleased to announce ... the professional staff of its Compliance Department. , Evelyn ... State University-Mortiz College of Law. Prior to joining ERISAPros, ... several Fortune 500 companies as well as several privately ... Her experiences range from benefit plan design, vendor management, ...
(Date:2/28/2015)... 28, 2015 In recent years Medical Marijuana ... practicing physicians as a way for them to expand their ... Cannabis as medicine. Since the FDA still lists Cannabis as ... available to licensed physicians that can help guide them ... Deborah Malka in Santa Cruz, CA is a leader ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 The Heart ... now a distributor of the machine. The Heart Fit ... their license, like a franchise model. The goal is ... and reverse heart disease. To buy External Counterpulsation ... Clinic can help individuals through this process and achieve ...
(Date:2/28/2015)... Fredericton, NB (PRWEB) February 28, 2015 ... call center software suite for Asterisk, are pleased to ... the highly successful 5.7 and 5.8 versions of Q-Suite, ... as well as a number of new features to ... be Q2 2015. , Q-Suite 5.9 will add features ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 ... of outsourced sales, marketing and supply chain management ... BIOTA Botanicals, is bringing its award winning solutions ... BIOTA Botanicals’ products are specifically created to combat ... experts, BIOTA is committed to marrying science with ...
Breaking Medicine News(10 mins):Health News:ERISAPros Recruits Evelyn King, J.D. and Carolyn Roddy, J.D. to its Professional Staff 2Health News:Reputable Cannabis Doctor In Santa Cruz and Monterey Joins the Medical Cannabis Network 2Health News:Clinicians Can Now Purchase External Counterpulsation with Heart Fit Clinic 2Health News:Indosoft Proudly Announces Q-Suite 5.9 Call Center Software for Asterisk 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 3
... Save the Children By Charles ... WESPORT, Conn., Oct. 24 The dramatic images,of wildfires ... on,children not only in the immediate area where the ... country who are watching the,destructive power of the flames ...
... Company Becomes First to Leverage Zagat,s, Expertise to Survey ... Rate Experiences Using ... Oct. 24 WellPoint, Inc., the,nation,s largest health benefits ... of a new online survey tool that will allow,consumers ...
... Pennsylvania has reversed the medical malpractice trend, ... said that Medical Care Availability and Reduction of ... since he took office and, as,a result of ... "Pennsylvania is a success story when it ...
... a novel,medical humidifier, was awarded a prestigious R&D ... PARI Innovative Manufacturers, a leading,manufacturer of nebulizers and ... gases are heated and humidified with the aim ... greater control,of patient comfort. The award, selected ...
... -- Combat physicians in war-torn areas like Iraq and ... require massive blood transfusions (MT), and thereby increase a ... the October issue of The Journal of the American ... of a combination of three variables -- assessed immediately ...
... induced in healthy volunteers, according to a study by ... Center for Medical Cannabis Research (CMCR.) However, the ... the placebo controlled study of 15 subjects, a low ... provided moderate pain relief, and a high dose increased ...
Cached Medicine News:Health News:How to Help Children Cope With the California Wildfires 2Health News:How to Help Children Cope With the California Wildfires 3Health News:How to Help Children Cope With the California Wildfires 4Health News:WellPoint Taps Zagat Survey to Help Consumers Rate Experiences with Their Doctors 2Health News:WellPoint Taps Zagat Survey to Help Consumers Rate Experiences with Their Doctors 3Health News:Governor Rendell Says Mcare Claims and Costs Are 50 Percent Lower Than in 2003 2Health News:PARI's Hydrate Wins Prestigious R&D 100 Award 2Health News:Early predictive model may be new 'weapon' against leading cause of death on battlefield 2Health News:Smoked cannabis proven effective in treating neuropathic pain 2
... IgG test is intended for qualitatively,detecting the ... antibodies to HSV-2 in human,sera. In conjunction ... the test is indicated for,testing sexually active ... the presumptive,diagnosis of HSV infection. The predictive ...
... 1 ELISA IgG test is intended for ... IgG class antibodies to HSV-1 in human ... ELISA IgG, the test is indicated for ... aiding in the presumptive diagnosis of,HSV infection. ...
... Horizontal separation offers many advantages ... separations to reduce re-spins and,re-mixes. The ... to,16.5 x 128mm, at speeds up ... Simply program the,digital time and speed ...
Ambion's barrier tips prevent cross-contamination of samples by means of an aerosol filter. They are RNase- and DNase-free and are ideal for handling RNA, PCR applications, and for working with radio...
Medicine Products: